If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Various strategies have been employed for constraining α-helices, including the non-covalent and covalent stabilization techniques; however, the all-hydrocarbon covalent link, termed a peptide staple, has been shown to have improved stability and cell penetrability, making this stabilization strategy particularly relevant for clinical applications.
=== Definition === The term "opioid" originated in the 1950s. It combines "opium" + "-oid" meaning "opiate-like" ("opiates" being morphine and similar drugs derived from opium). The first scientific publication to use it, in 1963, included a footnote stating, "In this paper, the term, 'opioid', is used in the sense originally proposed by George H. Acheson (personal communication) to refer to any chemical compound with morphine-like activities". By the late 1960s, research found that opiate effects are mediated by activation of specific molecular receptors in the nervous system, which were termed "opioid receptors". The definition of "opioid" was later refined to refer to substances that have morphine-like activities that are mediated by the activation of opioid receptors. One modern pharmacology textbook states: "the term opioid applies to all agonists and antagonists with morphine-like activity, and also the naturally occurring and synthetic opioid peptides". Another pharmacology reference eliminates the morphine-like requirement: "Opioid, a more modern term, is used to designate all substances, both natural and synthetic, that bind to opioid receptors (including antagonists)". Some sources define the term opioid to exclude opiates, and others use opiate comprehensively instead of opioid, but opioid used inclusively is considered modern, preferred and is in wide use.
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic of the arylcyclohexylamine class structurally related to PCP. It has been sold online as a designer drug. It has been used across Europe and the United States. It acts mainly as an NMDA receptor antagonist, though it has also been found to interact with the sigma σ1 receptor and the serotonin transporter.
Sources: en.wikipedia.org
=== Invasion of Afghanistan, 2002–2003 === After the 11 September attacks against the United States, Washington launched the Global War on Terrorism (GWOT). The 82nd Airborne Division was deployed to Afghanistan as part of Operation Enduring Freedom within the area of responsibility of the Central Command (CENTCOM), with a Task Force (TF). In June 2002, the division's Task Force Panther, made up of elements from the 505th Parachute Infantry Regiment (505th PIR) and other divisional units, was deployed in combat. In January 2003, this force was replaced by Task Force Devil, composed of the 504th PIR and other divisional units.
Membrane interaction of alpha-synuclein modulates or affects its rate of aggregation. The membrane-mediated modulation of aggregation is very similar to that observed for other amyloid proteins such as IAPP and abeta. Aggregated states of alpha-synuclein permeate the membrane of lipid vesicles. They are formed upon interaction with peroxidation-prone polyunsaturated fatty acids (PUFA) but not with monounsaturated fatty acids and the binding of lipid autoxidation-promoting transition metals such as iron or copper provokes oligomerization of alpha-synuclein. The aggregated alpha-synuclein has a specific activity for peroxidized lipids and induces lipid autoxidation in PUFA-rich membranes of both neurons and astrocytes, decreasing resistance to apoptosis. Lipid autoxidation is inhibited if the cells are pre-incubated with isotope-reinforced PUFAs (D-PUFA).
These kingdoms were defined as "the viceroyalties of New Spain (Mexico), Peru, New Granada, and Buenos Aires, and the independent captaincies general of the island of Cuba, Puerto Rico, Guatemala, Chile, Province of Venezuela, and the Philippines." This plan was criticized for providing unequal representation to Spanish America; nevertheless, throughout the end of 1808 and early 1809, the regional capitals elected candidates, whose names were forwarded to the capitals of the viceroyalties or captaincies general. Several important and large cities were left without direct representation in the Supreme Junta. In particular Quito and Chuquisaca, which saw themselves as the capitals of kingdoms, resented being subsumed in the larger Viceroyalty of Peru and Viceroyalty of the Río de la Plata respectively. This unrest led to the establishment of juntas in these cities in 1809, which were eventually quashed by the authorities within the year. An unsuccessful attempt at establishing a junta in New Spain was also stopped.
Sources: en.wikipedia.org
In the following years, it became the basis for the prosecutions of the opposition and the officers during the imposition of the totalitarian regime in the country. Between 23 and 31 January, Kimon Georgiev visited Moscow, where he met Joseph Stalin and Georgi Dimitrov for the first time. The main purpose of the visit was the conclusion, with Soviet mediation, of an alliance treaty between Bulgaria and Yugoslavia. Secret letters to the treaty envisaged the future creation of a federation, without specifying whether on an equal basis between the two countries, which Bulgaria insisted on, or by incorporating Bulgaria into Yugoslavia as a sixth republic, which was the Yugoslav position. The treaty was never concluded because of the opposition of the United Kingdom and the United States, who believed that Bulgaria could not act independently until a peace treaty was concluded. On 9 February 1945, Kimon Georgiev gave a report on the government's work to the First Congress of the Fatherland Front. Days after the first executions under the decision of the so-called People's Court, he deplored the "cases of self-destruction, arbitrariness and violence" that had been allowed to take place, claimed that they had been curbed quickly, and expressed satisfaction at their being channeled through the People's Court. He states that the constitution and "the rights and liberties of the Bulgarian people" have been restored, although the Council of Ministers rules by ordinance-laws and political organizations outside the Fatherland Front have not been legalized.
== Purification == Purification is achieved by differential centrifugation – the sequential increase in gravitational force results in the sequential separation of organelles according to their density.
==== Extraction ==== Extraction of polyphenols can be performed using a solvent like water, hot water, methanol, methanol/formic acid, methanol/water/acetic or formic acid. Liquid–liquid extraction can be also performed or countercurrent chromatography. Solid phase extraction can also be made on C18 sorbent cartridges. Other techniques are ultrasonic extraction, heat reflux extraction, microwave-assisted extraction, critical carbon dioxide, high-pressure liquid extraction or use of ethanol in an immersion extractor. The extraction conditions (temperature, extraction time, ratio of solvent to raw material, particle size of the sample, solvent type, and solvent concentrations) for different raw materials and extraction methods have to be optimized. Mainly found in the fruit skins and seeds, high levels of polyphenols may reflect only the measured extractable polyphenol (EPP) content of a fruit which may also contain non-extractable polyphenols. Black tea contains high amounts of polyphenol and makes up for 20% of its weight. Concentration can be made by ultrafiltration. Purification can be achieved by preparative chromatography.
=== 18 June === Ukrainian forces retook the village of Tykhe, west of Vovchansk. In Russia, the governor of Rostov Oblast claimed that several oil storage tanks were set on fire by a drone strike in Azov that destroyed 5,000 cubic metres of petroleum products. An oil depot in Krasnodar Krai was struck by Neptune missiles according to local sources, damaging a pipeline, “technical facilities” and starting a fire. No casualties were reported. A Ukrainian court sentenced a resident of Donetsk Oblast to 15 years' imprisonment for spying on Ukrainian positions on behalf of Russia during the Battle of Bakhmut. Swiss authorities claimed to have foiled an assassination attempt aimed at the Ukrainian peace summit, saying that a Russian diplomat was arrested a “few weeks” prior after trying to buy firearms. Ukrainian military observer Kostyantyn Mashovets claimed that the Russian Central Grouping of Forces has about 87,000 personnel, 365 tanks, 864 armored combat vehicles, of which about 68,000-70,000 personnel, 310-320 tanks, and about 576 armored fighting vehicles are currently deployed in the Pokrovsk direction.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.